Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Iovance Biotherapeutics (IOVA) over the last 7 years, with Q3 2025 value amounting to $14.3 million.

  • Iovance Biotherapeutics' Non-cash Items fell 377.41% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.3 million, marking a year-over-year decrease of 377.41%. This contributed to the annual value of $14.1 million for FY2024, which is 5540.12% down from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Non-cash Items is $14.3 million, which was down 377.41% from $14.7 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Non-cash Items high stood at $646.7 million for Q2 2023, and its period low was $6.2 million during Q2 2024.
  • Over the past 3 years, Iovance Biotherapeutics' median Non-cash Items value was $14.7 million (recorded in 2025), while the average stood at $89.1 million.
  • Over the last 5 years, Iovance Biotherapeutics' Non-cash Items had its largest YoY gain of 146245.61% in 2024, and its largest YoY loss of 9903.67% in 2024.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Non-cash Items stood at $31.7 million in 2023, then plummeted by 55.4% to $14.1 million in 2024, then grew by 1.4% to $14.3 million in 2025.
  • Its last three reported values are $14.3 million in Q3 2025, $14.7 million for Q2 2025, and $14.6 million during Q1 2025.